Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

9.1%

2 terminated out of 22 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

14%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

60% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (4)
P 1 (1)
P 2 (7)
P 3 (3)

Trial Status

Recruiting6
Unknown4
Active Not Recruiting4
Completed3
Not Yet Recruiting2
Terminated2

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT07549399Phase 3Not Yet Recruiting

SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

NCT03978663Not ApplicableActive Not RecruitingPrimary

Three Fraction Radiation to Induce Immuno-Oncologic Response

NCT04947098Recruiting

Prevent Cancer- Greenville

NCT04217356Active Not Recruiting

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

NCT05498272Phase 2Recruiting

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

NCT05482880Completed

Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region

NCT05557487Recruiting

Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration

NCT06020443Not ApplicableActive Not RecruitingPrimary

Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France.

NCT06908031Phase 2Recruiting

SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer

NCT06046625Active Not Recruiting

Needs and Preferences of Patients With Head-neck Cutaneous SCC

NCT06277050Phase 3Recruiting

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

NCT06327568Recruiting

Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens

NCT05120622Phase 1Withdrawn

Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer

NCT02308280Phase 2Completed

Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

NCT06041490Phase 2Not Yet Recruiting

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

NCT05254899Phase 2Unknown

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

NCT04905329Unknown

A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

NCT04334993Phase 2Unknown

Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

NCT04740866Not ApplicableUnknownPrimary

Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer

NCT03343249Not ApplicableCompletedPrimary

Adjunctive Smart Phone Based Smoking Cessation Treatment

Scroll to load more

Research Network

Activity Timeline